Your donation can help us fund promising cancer research and world-class facilities to increase cancer survivorship in a number of ways.
|
General gifts
|
We warmly invite you to become a Peter Mac supporter, where your gift will help us give the best possible care to people with cancer, both now and in the future.
|
Our annual grants program
|
The Foundation's grants program awards funds to strategically viable initiatives that hold the most promise for people with cancer. Since 2003, over $1.3 million has been awarded to 23 project grants. Our committee works closely with Peter Mac leadership to ensure a transparent, accountable process and the best use of philanthropic funds. You can read more about the promising projects we have supported in our call the Foundation office.
There are a range of significant funding opportunities at Peter Mac for donors who are interested in selecting a project that have been endorsed as a priority need. The Foundation welcomes the opportunity to discuss these projects with interested donors. A snapshot of some currently available is set out below. Please contact us if you would like to learn more about these funding needs.
|
annual report.
|
Gifts for Specific Purposes
|
Donors wishing to contribute to a particular initiative, such as a research program or medical equipment, can choose to direct their gift to projects we consider to be in the best strategic interest of the Centre.
We are happy to act as a conduit for donor directed grants, ensuring your contributions are appropriately allocated and tracked. If you'd like to find out more about how you can support specific projects at Peter Mac, please contact the Foundation.
|
There are a range of significant funding opportunities at Peter Mac for donors who are interested in selecting a project that have been endorsed as a priority need. The Foundation welcomes the opportunity to discuss these projects with interested donors. A snapshot of some currently available is set out below. Please contact us if you would like to learn more about these funding needs.
|
| | | Overcoming chemo-resistance in leukaemia: development of an in vivo model of chronic lymphocytic leukaemia (CLL) that better predicts responses to novel chemotherapeutics.
CLL is the most common form of leukaemia in the Western world, with men affected twice as often as women. Unfortunately, many patients develop resistance to existing chemotherapeutic drugs and their life expectancy is severely reduced, despite good response rates initially.
This project aims to provide a means of obtaining data that more accurately predicts whether CLL patients will respond to new chemotherapeutic strategies.
|
| Research - Cancer
Immunology
|
| | Do P53 mutations predict response to the new biological therapies bortezomib, thalidomide and lenalidomide in relapsed/refractory plasma cell myeloma?
Myeloma remains an incurable malignancy although several new and novel treatments have improved the outlook for patients with this disease. Targeting the right drug at the right time is one of the future goals to improve the treatment pathway of myeloma. This project will explore the role of 3 new biological agents bortezomib, thalidomide and lenalidomide in one common genetic subset in patients with myeloma. The study will provide valuable information for correlation with responses to new agents and treatment schedules being assessed in future clinical trials.
|
| Department of Haematology & Medical Oncology
|
| | Needs assessment of women undertaking premenopausal, risk reducing bilateral salpingo-oophorectomy (BSO)
Women at high risk of breast and ovarian cancer often undergo a surgical procedure that involves the removal of ovaries and fallopian tubes called bilateral salpingo-oophorectomy (BSO) to reduce their risk.
This project will study the long-term effects of BSO including osteoporosis and menopausal symptoms, as well as a range of potential psychological effects of premature menopause. The outcomes will enable researchers to fully inform women considering this procedure, and so that an appropriate support structure for these women can be developed.
|
| Department of Haematology & Medical Oncology
|
| |
|
